“Our team is executing well, and we have confidence in we will grow for the balance of the year.”

In context

“a combination of multiple things. Including the fact that diagnosis rates are improving. We've improved access, and therefore have had strong new patient starts, certainly versus last year, more than 70% and versus Q4, almost 20% new patient start growth. And continued compliance with our existing base of patients. And all of that has driven very, very strong volume growth year over year and sequentially. And we are managing that revenue growth despite the offset of the impact of IRA Part D redesign that Dave spoke to. Now we're obviously seeing the impact of competition, principally a Truby and principally on newly diagnosed patients. We'll continue to stay close and monitor that. And how that evolves and how Amboutra settles into the market as well. But the year is off to a good start. Our team is executing well, and we have confidence in we will grow for the balance of the year. Albert Bourla: Thank you. Alexandre, can you comment on Vintekl in the international? Alexandre de Germay: Yeah. Absolutely. So we had also a good growth of 36% this quarter above expectations from the analyst. What's driving that is essentially a significant increase in our treated population. We have actually reached a 52% growth in patients treated on Binda. In Q1 versus Q1 last year. So very healthy trends. And we see that this trend will continue for essentially three reasons. One, because our diagnosis rate has the potential to expand in pretty much all our key markets outside of the US too. Because of our profile is differentiated and will support our standard of care status, we believe in our key market. And three, which is often underestimated, we, after three years of hard work,”